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Vaccination stands as one of the most successful public health measures of the last century. New
approaches will be needed, however, to develop highly effective vaccines to prevent tuberculosis, HIV-
AIDS, andmalaria and to eradicate polio. Current advances in immunology and technology have set the stage
for rational vaccine design to begin a ‘‘Decade of Vaccines.’’Introduction: A Brief History
of Vaccines
The notion of protective immunity can be
traced back to the observation in the fifth
century BCE that individuals who had
recovered from disease during the Plague
ofAthenswereprotected fromsubsequent
attacks. However, the birth of the science
of immunology is most readily attributed
to the demonstration by Jenner at the
end of the 18th century CE that individuals
intentionally inoculated with material from
cowpox-infected cattle were protected
from smallpox. This demonstration preda-
ted evidence for the microbial (i.e., germ)
origin of infectious diseases obtained by
Koch and Pasteur. It also predated the
elucidation of the immunological factors
underlying this protective effect by von
Behring and many others. These ‘‘immu-
nologists’’ went on to develop this field as
a discipline and to illuminate the crucial
role of immunity and inflammation in infec-
tious diseases and in many other aspects
of human physiology (Allen et al., 1999).
Over the years, the fields of immu-
nology and clinical vaccinology diverged:
immunology became progressively fo-
cused on model systems that allowed
its intricacies to be probed in cellular
and molecular detail, whereas vaccinol-
ogy addressed more practical problems,
focusing on humans and other species
for which vaccines were intended. Absent
a knowledge-based toolkit by which to
reliably induce protective immunity to
the pathogens of interest, vaccinology
has been left to rely almost solely on
empirical, trial-and-error approaches not
so different from Jenner’s, approaches
that seek to mimic the processes of
natural infection while reducing the unto-
ward effects to an acceptable level.Nonetheless, vaccinology has been a
stunning success, with vaccination being
one of the greatest public health mea-
sures of the past century, and arguably
the most cost effective of all (Centers for
Disease Control and Prevention, 1999).
The eradication of smallpox in 1977 is a
landmark achievement. The potential for
eradication of polio is at hand, although
both public health and immunobiological
challenges remain (Serazin et al., 2010).
The development of rotavirus vaccines
offers the promise of saving the lives
of the more than 500,000 young children
worldwide who die from diarrheal illness
caused by this virus each year (Madhi
et al., 2010; Richardson et al., 2010).Hae-
mophilus influenzae type b, pneumo-
coccal, and meningococcal polysaccha-
ride-protein conjugate vaccines have
been a major success in the developed
world countries where they are in com-
mon use, reducing and in some cases
nearly eliminating pneumonia, sepsis,
and meningitis due to these pathogens.
And if the benefits of these conjugate
vaccines can be extended to children in
other parts of the world, more than one
million childhood deaths could be pre-
vented (http://www.who.int/immunization_
monitoring/burden/en/).
These conjugate vaccines have
achieved such great success because
they convert the antibody responses
to the target polysaccharide from
T cell-independent to T cell-dependent
responses. As a result, the vaccines
are vastly more immunogenic in the
young children at greatest risk than is
the infection with the pathogen itself.
This Lasker Award-winning achievement
stands alone among the achievements
to date in vaccinology as the only clearImmunity 33example of rational vaccine design
driven by and dependent on knowledge
derived from the fundamental immuno-
logical observations—made by Land-
steiner, Avery, and Goebel—decades
earlier (http://www.laskerfoundation.org/
awards/1996clinical.htm).
Although there has been a welcome
and substantial increase in vaccine
discovery and development efforts within
industry and in the public sector in the
recent past, this increase has not been
matched by a comparable increase in
the novelty of vaccine concepts or in
the predictability of the process. Surely,
vaccine discovery and development can
become more rational, and they must do
so to achieve the progress envisioned by
Bill and Melinda Gates and expressed as
a challenge at the 2010 World Economic
Forum. Their challenge was to make this
the ‘‘Decade of Vaccines,’’ a decade in
which eight million children would be
saved fromdeaths potentially preventable
by vaccines. To succeed, recent gains
in our understanding of basic immu-
nology, microbial pathogenesis, and
immune evasion, together with techno-
logical innovations in a variety of other
fields, must be applied to create, test,
and refine candidate vaccines; to study
the response to vaccines in humans
in vivo in a more holistic, expeditious,
and iterative manner; and to refine animal
models so they are more informative and
predictive of human vaccine responses.
The State of the Art of Vaccine
Immunology
The series of Reviews in the current issue
of Immunity provide a complementary,
contemporary perspective on the issues
described above. These articles discuss, October 29, 2010 ª2010 Elsevier Inc. 437
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science, including the determinants of
vaccine-induced immunity; tools for the
induction of effective immunity; concep-
tual frameworks to identify vaccine tar-
gets and seek causal correlates of protec-
tion; and progress toward effective
vaccines for tuberculosis, HIV-AIDS, and
malaria. Below we highlight some key
elements from each review article.
Vaccine-Induced Immunity:
Molecular, Cellular, and Anatomical
Determinants
Three articles in this issue together cover
the molecular, cellular, and anatomical
determinants of vaccine-induced immu-
nity. Vaccination induces immunological
memory that protects against subsequent
natural infection by a pathogen. Sallusto
et al. (2010) describe a process for
vaccine development—that they term
analytic vaccinology— based on analyz-
ing memory B cells and memory T cells
to understand the molecular basis by
which they can provide protection against
infection with particular pathogens. The
observed effects can then be refined and
enhanced as part of rational vaccine
design, seeking not only to optimize the
magnitude but the duration and functional
qualities of memory T cell and B cell/
plasma cell responses. Sallusto et al. cite
several studies, for instance, that use
newly developed technologies to compre-
hensively characterize the human anti-
body response to infection. Despite the
diversity of HIV-1 and influenza viruses,
these studies identified broadly neutral-
izing antibodies for each virus, thereby
identifying conserved epitopes which
can guide new vaccine development.
Diverse pathogens invade at mucosal
surfaces, anda localizedmucosal immune
response is required to protect against
such invaders as HIV andM. tuberculosis.
Mucosal vaccines—those administered
orally or by inhalation— can induce the
production of antibodies that inhibit the
earliest steps in infection, including
pathogen attachment, but few mucosal
vaccines have been successfully devel-
oped to treat human infections. Chen
and Cerutti (2010) attribute this lack in
part to an incomplete understanding
of the finely tuned nature of mucosal
immunity, which evolved to detect patho-
gens while balancing tolerance to the
vast community of microbes inhabiting438 Immunity 33, October 29, 2010 ª2010 Elmucosal surfaces. A major challenge is
to induce sustained mucosal immunity
while not perturbing this balance either
toward overstimulation and consequent
inflammation or toward counterproduc-
tive tolerance. In addition, challenges in
developing a broadly effective vaccine
arise because of mucosal physiology
specific to the elderly and to women.
Nevertheless, as Chen and Cerutti (2010)
further note, the complex regulation of
mucosal immunity also provides opportu-
nities, such as the potential to enhance
immune response by dietary supplemen-
tation with vitamin A, perhaps particularly
relevant for populations with inherent
nutritional deficiencies.
Dendritic cells, once activated by
foreign antigens via the pattern recogni-
tion receptors of innate immunity, initiate
an adaptive immune response to these
antigens. As discussed by Palucka et al.
(2010), the type of immune response initi-
ated depends on the type of dendritic cell
and also on the particular innate immune
signals received. These properties make
dendritic cells attractive potential targets
when designing vaccines to produce
a specific immune response. Palucka
et al. (2010) note, for instance, that plas-
macytoid dendritic cells found in blood
have a number of features that could
make them good targets for new antiviral
vaccines. Similarly, on the basis of evi-
dence that Langerhans cells, a dendritic
cell subset found in the skin, are function-
ally specialized to activate cellular immu-
nity, Palucka et al. (2010) propose that
these cells may be good targets of
vaccines designed to prevent chronic
diseases, including tuberculosis, HIV/
AIDS, and malaria. A key remaining chal-
lenge in such vaccine design is deter-
mining the best mechanism to target the
dendritic cell subset.
Tools for the Induction of Effective
Immunity
When there is a need to increase the
immune response to a vaccine or to alter
the types of induced immunity, there are
powerful tools at hand. These tools are
particularly relevant for targeting patho-
gens for which natural infection does not
induce effective immunity. Adjuvants,
vaccine components that enhance immu-
nogenicity, are one such tool. Complete
Freund’s adjuvant, developed empirically
and long used in experimental systems,sevier Inc.consists of heat-killed mycobacteria in
a water-in-oil emulsion formulation, with
both the sourceof antigens and the formu-
lation contributing to activity. As dis-
cussed by Coffman et al. (2010), there is
a current emphasis on rationally designing
adjuvants on the basis of known corre-
lates of immune protection, rather than
the empirical approach used historically.
Most adjuvants are thought to work
primarily by stimulating innate immunity,
and they are most effective when used in
combination to stimulate multiple immune
pathways, as would be the case during
natural infection or with live, attenuated
vaccines (Coffman et al., 2010). An excel-
lent example highlighted by Coffman et al.
(2010) is the RTS,Smalaria vaccine, which
conferred protection that was dependent
on the combination of adjuvants. Coffman
et al. (2010) conclude their Review by
noting that adjuvant research leading to
clinical trials, even though highly directed
to prevent disease, may ultimately yield
awealth of data on the immune responses
of healthy humans.
Another tool that can be usedwhen live,
attenuated vaccines are not feasible is to
deliver pathogen antigens by vectors.
Vaccine vectors include viruses, bacteria,
DNA, and RNA. As discussed by Liu
(2010), vectored vaccines can be exqui-
sitely tailored in terms both of the cell
types and cellular compartments targeted
and in terms of how the antigens are deliv-
ered. One striking example highlighted
by Liu (2010) is a successful veterinary
rabies vaccine, incorporated into food
bait, which used an altered version of
the human smallpox vaccine (modified
vaccinia Ankara) as a vector to deliver
rabies virus antigen tomultiple wild animal
species. The immune response to the
vector itself must be taken into account
during vaccine development, and it was
a source of concern in the STEP trial of
an HIV vaccine employing an adenovirus
vector. On a positive note, Liu (2010)
emphasizes that the efficacy of vectored
vaccines can be enhanced by using two
different vectors—or two different types
of vaccines—in series in prime-boost
immunization, and mixed modality prime-
boost immunization trials with HIV
vaccines are currently underway.
Conceptual Frameworks
One common theme in this issue’s
vaccine review series is the importance
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system. Two conceptual frameworks
that emphasize taking the broadest
possible perspective are reverse vacci-
nology (Sette and Rappuoli, 2010) and
‘‘systems vaccinology’’ (Pulendran et al.,
2010). Reverse vaccinology begins with
bioinformatic analysis of a pathogen
genome to comprehensively identify anti-
gens in silico. Candidate antigens are
then progressively eliminated by experi-
mental tests until candidates for vaccine
trials remain. This sequence is a reversal
of the usual work flow in which extensive
analysis requiring culturing the organism
comes first and bioinformatic analysis
later. In its first usage, reverse vaccinol-
ogy quickly yielded a type b meningo-
coccal vaccine candidate, which had
previously seemed out of reach. In a
similar ‘‘reverse’’ strategy used in a recent
study highlighted by Sette and Rappuoli
(2010), in silico prediction of MHC-binding
vaccinia virus peptides yielded a compre-
hensive list of the epitopes responsible for
the murine T cell response to the virus.
Sette and Rappuoli (2010) note that such
strategies for generation of unbiased
and comprehensive antigenic maps of
pathogens are likely to be widely applied
in the coming years.
Systems vaccinology—a systems
biology approach to vaccinology—
attempts to capture the network of rela-
tionships that integrate the parts of the
immune system, from molecules to cells
to tissues, and use it to predict the func-
tioning of the system as a whole as it
applies to vaccine science. In one exam-
ple discussed by Pulendran et al. (2010),
human gene expression signatures were
identified that could predict the CD8+
T cell response induced by the highly
successful yellow fever vaccine, and these
signatures implicated the integrated
stress response in vaccine-induced
immunity. Extending such studies to other
vaccines could yield sets of gene expres-
sion signatures, each predictive of a
different facet of vaccine immunogenicity.
Integrated into a ‘‘vaccine chip,’’ these
signatures could be used both to guide
the design of new vaccines and to identify
vaccinated individuals with suboptimal
responses (Pulendran et al., 2010). Pulen-
dran et al. point out that a systems biology
approach could have many additional
uses. The approach could be used to
develop co-correlates of protective immu-nity that might reflect vaccine efficacy
better than the single variables commonly
used and might be applied when vaccine
efficacy is determined by a balance
between elements of humoral and cellular
immunity, for instance. More generally,
this is a powerful type of approach for
revealing new biology and could be used
to systematically determine the detailed
mechanism of action of adjuvants so that
they can be used most effectively.
Although systems-level analysis in
biology is not a replacement for more
focused efforts, both Pulendran et al.
(2010) as well as Germain (2010) discuss
some of the research programs being
created to facilitate such analysis and
capitalize on the latest technologies.
Akin to the multiple efforts underlying the
human genome project, these programs
will encompass a consortium of human
immune profiling centers, academic insti-
tutes, and linked government laborato-
ries. The common goal is to characterize
the human immune system in health and
when perturbed by infection, vaccination,
or genetic disease. These research
programs will help bridge basic research
on vaccines with ongoing clinical trials,
ensuring not only that basic research
guides clinical trial design but also that
information gained from clinical trials is
used to drive basic research (Pulendran
et al., 2010). The opportunities for new
discovery added by this cycling of infor-
mation will in turn help ensure that during
vaccine design what should be measured
always trumps what can be measured
(Germain, 2010).
Vaccines for Tuberculosis,
HIV-AIDS, and Malaria
For three diseases that are critical global
health threats—tuberculosis, HIV-AIDS,
and malaria—there are no highly effective
vaccines. Three perspective articles in the
current issue describe the vaccine
research underway directed against these
diseases. Kaufmann (2010) reviews the
vaccination strategies directed against
tuberculosis. He notes that the current
live attenuated BCG vaccine protects
against severe disease in infants, but is
ineffective against adult pulmonary dis-
ease. Despite the BCG vaccine being
given four billion times since its first use
90 years ago, its mechanism of protective
immunity is unclear. Nevertheless, of the
11 candidate vaccines now in clinicalImmunity 33trials, two are recombinant forms of BCG
and seven are subunit booster vaccines
to follow priming with BCG; the remaining
two candidates do not contain live
bacteria and are not meant to be adminis-
tered with BCG, given that they are
targeted to individuals coinfected with
M. tuberculosis and HIV (Kaufmann,
2010). All these candidate vaccines aim
to delay active disease, not to prevent or
eliminate infection, which are goals for
the future. Echoing Pulendran et al.
(2010), Kaufmann (2010) concludes that
achieving these two future goals is likely
to require effective cycling of informa-
tion between basic research and clinical
trials.
McElrath and Haynes (2010) review the
vaccination strategies directed against
HIV-1. They note the many aspects of
HIV-1 biology that complicate develop-
ment of a vaccine, including the fact that
HIV-1 evolution within its hosts has
created a worldwide level of viral diversity
perhaps beyond the reach of a single
vaccine candidate. In addition, key data
that drive rational vaccine development
remain unknown for HIV-1, such as corre-
lates of protective immunity and how pre-
dicted correlates might best be elicited.
Despite these challenges, the recently
published results of the RV144 vaccine
trial conducted in Thailand demonstrated
for the first time that a vaccine regimen
could reduce HIV-1 infection rates, in
this case by 31%. The RV144 trial used
a recombinant canarypox vector express-
ing three HIV-1 proteins as a prime and
two different recombinant HIV-1 gp120
envelope glycoproteins with alum adju-
vant as a boost. The observed reduction
in infection, albeit modest, is certainly
grounds for optimism, and determining
the correlates of protective immunity in
this trial is one avenue forward (McElrath
and Haynes, 2010).
Good and Doolan (2010) review the
vaccination strategies directed against
malaria. As is the case for developing
vaccines targeting HIV, a challenge in tar-
geting the malaria parasite is its diversity,
not only because of the different Plasmo-
dium species that infect humans, but also
because of genetic mechanisms inherent
in Plasmodium that generate surface
antigen diversity. This challenge notwith-
standing, there has been recent success
in malaria vaccine efforts. The RTS,S
vaccine, consisting of a fusion protein, October 29, 2010 ª2010 Elsevier Inc. 439
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zoite protein fused to the hepatitis B
surface antigen—combined with an adju-
vant mixture, reduced infection in African
children by 30%–50%. For the vaccine
version currently in phase 3 clinical trials,
the adjuvants are monophosphoryl lipid
A and the saponin QS-21 in a liposomal
formulation. Good and Doolan (2010)
suggest that in parallel to developing
vaccines based on immunodominant
antigens, such as the circumsporozoite
protein, it is also important to move
forward with research aimed at inducing
a broader immune response, such as by
using live attenuated parasites.
Concluding Remarks
This series of Immunity Reviews frames
a number of the key issues in vaccine
science and identifies opportunities for
productively integrating immunology and
vaccinology. A closer working partnership
between these fields and with colleagues
in information, engineering, bioengineer-
ing, and biomaterials science is needed.
We propose that through such partner-440 Immunity 33, October 29, 2010 ª2010 Elships lies the path to accelerate the
development of vaccines for major global
disease threats. Knowledge gained
through these partnerships will help to
select which are the best candidates to
enter human vaccine trials, thereby
increasing the efficiency of these trials,
and ultimately will promote the creation
of vaccines that are less costly and more
practical for people in resource limited
settings where the burden of disease is
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